See the DrugPatentWatch profile for Adempas
What can replace Adempas (riociguat) for pulmonary arterial hypertension?
Adempas (riociguat) is used for pulmonary arterial hypertension (PAH) to improve exercise capacity and for certain cases of chronic thromboembolic pulmonary hypertension (CTEPH) where disease is inoperable or persistent after surgery. Alternatives depend on the exact diagnosis (PAH vs inoperable/persistent CTEPH) and risk profile.
In PAH, clinicians commonly use other PAH-targeted drug classes rather than switching to a single “one-size-fits-all” option:
- Endothelin receptor antagonists (ERAs)
- Phosphodiesterase-5 (PDE5) inhibitors
- Prostacyclin pathway therapies (including prostacyclin analogs, prostacyclin receptor agonists, and prostacyclin pathway agents)
In CTEPH, options often still include targeted medical therapy, but many patients are also evaluated for procedures such as pulmonary endarterectomy when feasible. The best alternative is strongly tied to operability and prior treatment.
How do PAH medication classes compare if you’re looking for a different option than Adempas?
If you’re considering “alternatives” to Adempas for PAH, the main comparison is by mechanism:
- ERAs block endothelin signaling, aiming to reduce vascular constriction and remodeling.
- PDE5 inhibitors improve the nitric oxide–cGMP pathway downstream from where riociguat works.
- Prostacyclin pathway therapies reduce pulmonary vascular resistance through prostacyclin signaling.
Which class fits depends on factors such as disease severity, how well you’re responding, blood pressure tolerance, comorbidities, and whether you’re already on combination therapy.
Is there an Adempas substitute for inoperable or persistent CTEPH?
For CTEPH that is inoperable or persists after pulmonary endarterectomy, the alternative pathway is usually still medical PAH/CTEPH-directed therapy, with additional emphasis on whether the patient has been fully evaluated for surgical or interventional options. Your care team’s choice typically reflects what has already been tried, symptom trajectory, and safety considerations.
What about drug “switching” versus adding another therapy?
People asking for Adempas alternatives are often really asking one of two things:
- Switch to a different monotherapy if Adempas is not tolerated or not working.
- Add another class on top of Adempas to intensify treatment.
In PAH, treatment escalation commonly uses combination strategies across different drug classes, guided by response and risk assessments. The exact sequence and choice vary by local practice and patient factors.
Are there safety issues when changing from Adempas to another PAH drug?
Switching PAH therapies can involve safety considerations, especially around blood pressure and interactions with drugs that affect the nitric oxide–cGMP pathway. Because Adempas directly targets this signaling route, any change should be coordinated with a clinician who can manage washout timing and interaction risk.
What should you ask your doctor to pick the right alternative?
To get a useful alternative plan, ask:
- Do you have PAH, inoperable CTEPH, or persistent CTEPH after surgery?
- What risk category am I in, and what treatment goal are we targeting?
- What class change are you recommending (ERA vs PDE5 inhibitor vs prostacyclin pathway), and why for my case?
- If this is a switch, what’s the transition plan and safety monitoring?
- If this is escalation, will you add on, and how will we judge response?
If you meant “natural” or non-drug alternatives
Adempas alternatives usually refers to other prescription PAH/CTEPH drugs. Non-drug supports (like supervised exercise and vaccinations) may help overall health, but they do not replace PAH/CTEPH medications for most patients with active disease.
If you tell me whether this is PAH or inoperable/persistent CTEPH, and what you’re trying to achieve (side effects, pregnancy planning, inadequate response, cost/availability), I can narrow the most relevant Adempas alternatives and the usual treatment comparisons.